Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest

Hisayoshi Takagi; T. Sasagawa; Y Osaka

doi:10.12891/ceog4029.2018

Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest

Hisayoshi Takagi, T. Sasagawa, Y Osaka

In: Clinical and Experimental Obstetrics & Gynecology · 2018 · vol. 45(2) , pp. 312–315 · doi:10.12891/ceog4029.2018 · W3036113552

article OA: bronze CC0 ⤵ 1 in-corpus citation

🔓 Open OA copy Full text JSON View on OpenAlex View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-07 ⓘ

This study found that increased follicle-stimulating hormone levels confirmed menopause in patients on dienogest, and the drug prevented endometriosis and adenomyosis recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-15 · read from full text ⓘ

This study investigated the optimal timing for discontinuing long-term dienogest treatment in climacteric patients by monitoring serum follicle-stimulating hormone and estradiol levels. Researchers administered 2 mg of dienogest daily for over twelve months to patients with endometriosis and adenomyosis, stopping the medication once hormone profiles indicated menopause. The results showed that an increase in FSH levels above 25.8 mIU/mL confirmed menopause, and no pain recurrence was observed in these patients one year after cessation. This paper is centrally about endometriosis and adenomyosis, specifically evaluating clinical management strategies for symptom control during the transition to menopause.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Purpose of investigation: The appropriate time for patients to discontinue dienogest (DNG) after long-term use has been a recent topic of debate. Therefore, this study evaluated the timing for discontinuation of DNG in climacteric patients suffering from endometriosis and adenomyosis. Materials and Methods: DNG was orally administered at 2 mg/day for more than 12 months. The serum estradiol (E2) and follicle-stimulating hormone (FSH) levels were measured every three to six months. DNG was discontinued when the hormone levels changed to those characteristic of menopause. Results: FSH levels in three patients increased to more than 25.8 mIU/mL during DNG administration. They were thus diagnosed as having entered menopause. There was no recurrence of pain in these patients at one year after discontinuation of DNG. Conclusion: An increase in serum FSH levels could help in confirming the diagnosis of menopause. In addition, DNG prevented the recurrence of endometriosis and adenomyosis.

Full text 1,644 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Keywords

- Dienogest - Endometriosis - Adenomyosis - Estradiol - Follicle-stimulating hormone

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works